The cost of treating substance abuse patients with and without comorbid psychiatric disorders.
about
An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment programComorbidity between hypomania and substance use disorders.Diagnostic cost groups (DCGs) and concurrent utilization among patients with substance abuse disorders.Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: the HUUTI study.Comorbid depression and substance abuse among safety-net clients in Los Angeles: a community participatory study.Women with comorbid substance dependence and psychiatric disorders in Sweden: a longitudinal study of hospital care utilization and costs.Opportunities for an improved role for nurses in psychoactive substance use: review of the literature.The role of continuing care in 9-year cost trajectories of patients with intakes into an outpatient alcohol and drug treatment programPsychiatric comorbidity and acculturation stress among Puerto Rican substance abusers.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?Clinical outcomes of an integrated treatment for depression and substance use disorders.Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports.Family Intervention to Prevent Depression and Substance Use Among Adolescents of Depressed Parents.Do client attributes moderate the effectiveness of a group cognitive behavioral therapy for depression in addiction treatment?Evaluating a brief, internet-based intervention for co-occurring depression and problematic alcohol use in young people: protocol for a randomized controlled trial.Correlates of major depressive disorder with and without comorbid alcohol use disorder nationally in the veterans health administration.Prevalence of co-occurring alcohol and other drug use in an Australian older adult mental health service.Clients with substance abuse and mental health concerns: a guide for conducting intake interviews.PTSD and substance use disorder among veterans: characteristics, service utilization and pharmacotherapy.Using information technology to evaluate the detection of co-occurring substance use disorders amongst patients in a state mental health system: implications for co-occurring disorder state initiatives.Recognizing comorbidity among drug users in treatment.Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment.Expenditures in mental illness and substance use disorders among veteran clinic users with diabetes.Patients with dual diagnoses or substance use disorders only: 12-step group participation and 1-year outcomes.Assessing the service linkages of substance abuse agencies with mental health and primary care organizations.Service utilization during and after outpatient treatment for comorbid substance use disorder and depression.Limiting inpatient substance use treatment: what are the consequences?The lived experience of community mental health nurses working with people who have dual diagnosis: a phenomenological study.Rates and sequelae of the coexistence of substance use and other psychiatric disorders.The role of academic psychiatry in leading health policy reform.Availability of integrated care for co-occurring substance abuse and psychiatric conditions.Changes in the pattern of substance abuse after the onset of psychosis.
P2860
Q24635217-8501958D-2EF6-4547-95B4-6E24C9130383Q33842423-10B1A098-705B-4D9A-8AC3-EC8DAC13CB31Q34623213-C85EBCBE-23C3-48EF-9D90-99596633CA2AQ34687009-1D90688E-68D9-465D-9E43-084122096479Q35146107-6B8C5FB4-6E8A-477B-B05B-8ADEF7CC4BD8Q35655210-5CB67E8C-7AA2-470C-AC32-3CC785E137D3Q35776421-DD4862D1-EEA0-4421-96A8-6CDF3D37FAB4Q35966127-ABCCD679-E895-4733-BBE1-6D4CE36A8AB8Q35987721-C9D5EBA6-F0DD-45A8-9C92-E3983D0844F2Q36059843-63DEE694-9FD8-450C-84FD-02650F12B443Q36228225-E1CFC505-2144-456B-8D45-C2568791757CQ36721086-58FFDAEC-A7D9-489C-8258-757A46F85010Q36866791-59A573CF-68CB-4D30-9525-4D832E26A4FEQ36945901-383B3014-437D-4DBD-AB34-CCD9D6F40413Q37059919-F73A06F0-95D1-4778-9C5A-08739C919FACQ37653505-3A73B828-E1BE-40F8-9D99-365E39DB3BFFQ38464022-1F0CA1F1-DB93-46BE-92E3-8241A9EB8FF8Q38913434-4BA0A510-05C5-4F21-8475-DE3A3171D4B5Q39614634-8874C3E8-ED01-4804-96F8-3CB8525A9D3AQ41684062-6BAA18B2-FE14-482C-8171-A14E335FA423Q43959511-8F5F1BFB-AABA-4E08-B70E-C3776C88CC21Q43996338-8440EADC-1CF6-4EF1-901A-C11A3846CBFAQ45205742-A7C48723-2BD9-4254-A776-1778DB802631Q45331883-3D57046B-CBCE-4EA7-8CDA-9DF138782089Q46120403-7C201E98-1344-461B-94FE-2F278303BE32Q46922244-540AADFC-56D8-4DDD-97FA-9F42E3FB67D0Q46981629-663DB8D9-70E5-4634-A110-4B9082F3ED14Q47629359-426EBD3F-9D50-467B-90F3-C17D20AE39D9Q47784976-74677C02-727C-40CE-B0AE-29AA35F06E20Q50106946-BC03FA3C-E59F-4F89-A6DA-4CDF1200B97FQ50632768-D6856042-D84A-4494-8AFD-7ED36B0FA40FQ51920239-3F40A5D3-AD48-448B-8751-A83E1E208D7FQ52287754-BF4251A2-4FB6-402D-B219-3D860C52667E
P2860
The cost of treating substance abuse patients with and without comorbid psychiatric disorders.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
The cost of treating substance ...... omorbid psychiatric disorders.
@en
The cost of treating substance ...... omorbid psychiatric disorders.
@nl
type
label
The cost of treating substance ...... omorbid psychiatric disorders.
@en
The cost of treating substance ...... omorbid psychiatric disorders.
@nl
prefLabel
The cost of treating substance ...... omorbid psychiatric disorders.
@en
The cost of treating substance ...... omorbid psychiatric disorders.
@nl
P356
P1433
P1476
The cost of treating substance ...... omorbid psychiatric disorders.
@en
P2093
P304
P356
10.1176/PS.50.10.1309
P577
1999-10-01T00:00:00Z